arrow
Y

Yoshihiko Tomita

Niigata University
H指数:56
被引数:2.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Nivolumab plus gemcitabine-cisplatin for previously untreated unresectable or metastatic urothelial carcinoma: an Asian subgroup analysis from the global phase 3 CheckMate 901 trial

纳武利尤单抗联合吉西他滨-顺铂用于既往未治疗的不可切除或转移性尿路上皮癌:一项来自全球III期CheckMate 901试验的亚洲亚组分析

2025-11-010
OAAI
Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274

高风险肌层浸润性尿路上皮癌的辅助尼洛替尼对比安慰剂:CheckMate 274研究的5年疗效和ctDNA结果

2025-10-170
OAAI
GWAS Identifies SNPs Associated With Severe Adverse Events and Efficacy in Advanced Renal Cell Carcinoma Treated With Nivolumab

全基因组关联研究(GWAS)鉴定出与接受纳武利尤单抗治疗的晚期肾细胞癌患者严重不良事件及疗效相关的单核苷酸多态性(SNP)。

2025-09-240
OAAI
Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial

来自随机III期CheckMate 9ER试验的尼鲁单抗联合卡博赞替尼治疗晚期肾细胞癌的最终分析

2025-09-230
OAAI
Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial

辅助性纳武利尤单抗在肌肉浸润性尿路上皮癌中的应用:随机III期CheckMate 274试验的探索性生物标志物分析

2025-08-070
PRE
Characterization of Patients with Lymph Node Only Metastatic Urothelial Carcinoma Treated with Nivolumab Plus Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin Alone from the CheckMate 901 Trial

CheckMate 901试验中,仅淋巴结转移性尿路上皮癌患者接受纳武利尤单抗联合吉西他滨-顺铂治疗与单独吉西他滨-顺铂治疗的特征分析

2025-05-200
OAAI
Avelumab D axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial

avelumab联合达沙替尼与舒尼替尼作为晚期肾细胞癌患者的一线治疗:JAVELIN Renal 101 III期试验的最终分析

2024-12-013
PRE
Nivolumab plus ipilimumab versus sunitinib for fi rst-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial

Nivolumab联合ipilimumab与舒尼替尼用于晚期肾细胞癌的一线治疗: CheckMate 214 III期试验的疗效和安全性的8年随访结果

2024-11-010
OAAI
Effect of HLA Genotype on Anti-PD-1 Antibody Treatment for Advanced Renal Cell Carcinoma in the SNiP-RCC Study
2024-05-170
OA
Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial

Nivolumab联合卡博替尼与舒尼替尼一线治疗晚期肾细胞癌: III期随机CheckMate 9ER试验的延长随访

2024-05-0118
OAAI
Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score (vol 83, pg 432, 2024)
2024-03-011
OA
Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial
2023-09-021
OAAI
Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score
2023-05-0114
OA